[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549278":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":35,"centralContacts":49,"locations":56,"responsibleParty":74,"collaborators":77,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":91,"minAge":92,"maxAge":30,"enrollmentInfo":93,"targetDuration":30,"studyType":96,"phases":97,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":59,"whyStopped":30,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Hvidovre University Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Single-arm open-label study in healthy volunteers","EXPERIMENTAL","Healthy volunteers will receive fisetin.",[13],"Drug: Fisetin",{"label":15,"type":10,"description":16,"interventionNames":17},"RCT - Treatment group","Older patients with multimorbidity will receive fisetin.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"RCT - Placebo group","PLACEBO_COMPARATOR","Older patients with multimorbidity will receive placebo.",[23],"Drug: Placebo",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Fisetin","Subjects will receive fisetin corresponding to 20 mg\u002Fkg\u002Fday for two consecutive days.",[15,9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Placebo","Subjects will receive a corresponding number of placebo capsules for two consecutive days.",[19],[36,40,42,44,47],{"name":37,"affiliation":38,"role":39},"Juliette Tavenier","Copenhagen University Hospital, Amager and Hvidovre","STUDY_CHAIR",{"name":41,"affiliation":38,"role":39},"Line Jee Hartmann Rasmussen",{"name":43,"affiliation":38,"role":39},"Morten B Houlind",{"name":45,"affiliation":38,"role":46},"Ove Andersen","PRINCIPAL_INVESTIGATOR",{"name":48,"affiliation":38,"role":39},"Jan O Nehlin",[50,54],{"name":37,"role":51,"phone":52,"phoneExt":30,"email":53},"CONTACT","+4538620640","juliette.tavenier@regionh.dk",{"name":41,"role":51,"phone":52,"phoneExt":30,"email":55},"line.jee.hartmann.rasmussen@regionh.dk",[57],{"facility":58,"status":59,"city":60,"state":30,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Department of Clinical Research, Copenhagen University Hospital Amager & Hvidovre","RECRUITING","Hvidovre","2650","Denmark","DK",{"type":65,"coordinates":66},"Point",[67,68],12.47708,55.64297,{"lat":68,"lon":67},[71,73],{"name":37,"role":51,"phone":72,"phoneExt":30,"email":53},"+45 38620640",{"name":41,"role":51,"phone":72,"phoneExt":30,"email":55},{"type":75,"investigatorFullName":45,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"SPONSOR_INVESTIGATOR","Head of Research, Clinical Professor, Principal Investigator",[78,80],{"name":79,"class":6},"University of Southern Denmark",{"name":81,"class":6},"Mayo Clinic","100549278","phase-1-pilot-trial-of-fisetin-in-healthy-volunteers-and-older-patients-with-multimorbidity-100549278",false,"NCT06431932","Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity","Pharmacokinetics, Safety, and Efficacy of Fisetin - A Phase I and Pilot Phase IIa Study","Fisetin HIGH","Healthy volunteers:\n\nInclusion Criteria:\n\n* Aged 20-35 years\n* suPAR levels \\\u003C3.5 ng\u002FmL (± 15% corresponding to assay variation)\n* Able to cooperate cognitively\n* Able to read and understand Danish\n* Women of childbearing potential must use effective contraception\n\nExclusion Criteria:\n\n* Body weight \\>100 kg\n* Inability to swallow pills\n* Pregnant and\u002For lactating\n* Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules\n* Presence of any condition that the investigator believes would put the subject at risk or would preclude the participant from successfully completing all aspects of the trial\n* Presence of known chronic diagnosis\n* Active acute illness\n* Prescribed medication, except contraceptives\n* Previous cancer diagnosis or treatment\n* Use of senolytic and other \"anti-aging\" supplements\n\nOlder patients with multimorbidity:\n\nInclusion Criteria:\n\nAt screening #1 during hospital admission:\n\n* Acutely hospitalized medical patient\n* Age ≥65 years\n* suPAR \\>5 ng\u002FmL (± 15% corresponding to assay variation)\n* Multimorbidity (≥2 chronic diagnoses)\n* Able to cooperate cognitively\n* Able to read and understand Danish\n\nAt screening #2 28 days after hospital discharge:\n\n* suPAR \\>5 ng\u002FmL (± 15% corresponding to assay variation)\n\nExclusion Criteria:\n\nAt screening #1 during hospital admission:\n\n* Body weight \\>100 kg\n* Inability to swallow pills\n* Known human immunodeficiency virus infection, active hepatitis B or C infection, invasive fungal infection\n* Uncontrolled (as per clinical judgment) pleural\u002Fpericardial effusions or ascites\n* New\u002Factive invasive cancer except non-melanoma skin cancers\n* Active cancer treatment or disseminated cancer\n* Known condition associated with major immunodeficiency\n* Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules\n* Use of senolytic and other \"anti-aging\" supplements\n\nAt screening #2 28 days after hospital discharge:\n\n* Body weight \\>100 kg\n* CRP \\>30 mg\u002FL (± 15% corresponding to assay variation)\n* Inability to swallow pills\n* Presence of any condition, or abnormal routine biochemistry test, that the investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial\n* Unstable (as per clinical judgment) major disorders, e.g., cardiovascular, renal, endocrine, immunological, hepatic disorder, or cancer\n* Estimated glomerular filtration rate (eGFR) \\\u003C15 ml\u002Fmin\u002F1.73 m2 or as per clinical judgment (e.g., risk of acute kidney injury)\n* Human immunodeficiency virus infection, known active hepatitis B or C infection, invasive fungal infection\n* Uncontrolled (as per clinical judgment) pleural\u002Fpericardial effusions or ascites\n* New\u002Factive invasive cancer except non-melanoma skin cancers\n* Active cancer treatment or disseminated cancer\n* Known condition associated with major immunodeficiency\n* Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules\n* Subjects taking strong inhibitors or inducers of CYP3A4 or as per clinical judgment\n* Subjects taking specified substrates with a narrow therapeutic range for CYP3A4 or as per clinical judgment\n* Subjects taking specified inhibitors, inducers, or substrates of CYP2D6, CYP2C9, or CYP2C8, or as per clinical judgment\n* Subjects regularly using drug classes or specific medications or as per clinical judgment\n* Use of senolytic and other \"anti-aging\" supplements",true,"ALL","20 Years",{"count":94,"type":95},60,"ESTIMATED","INTERVENTIONAL",[98,99],"PHASE1","PHASE2","The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models.\n\nWe will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe. We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.",[102,103],"Multimorbidity","Healthy",[105,106,107],"Senolytic","Pharmacokinetics","Chronic inflammation","2026-05-16",{"date":110,"type":111},"2026-05-19","ACTUAL",{"date":113,"type":111},"2026-03-24",{"date":115,"type":95},"2028-12-31",{"name":45,"class":6},1]